Sivik Global Healthcare LLC Acquires New Holdings in Merck & Co., Inc. $MRK

Sivik Global Healthcare LLC acquired a new stake in Merck & Co., Inc. (NYSE:MRK) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 30,000 shares of the company’s stock, valued at approximately $3,158,000.

Several other hedge funds have also recently bought and sold shares of the company. DLD Asset Management LP lifted its position in Merck & Co., Inc. by 30.1% in the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock valued at $3,986,675,000 after purchasing an additional 11,000,000 shares during the last quarter. Legal & General Group Plc lifted its position in Merck & Co., Inc. by 5.9% in the 3rd quarter. Legal & General Group Plc now owns 20,659,157 shares of the company’s stock valued at $1,733,923,000 after purchasing an additional 1,156,112 shares during the last quarter. Invesco Ltd. lifted its position in Merck & Co., Inc. by 16.6% in the 3rd quarter. Invesco Ltd. now owns 19,844,936 shares of the company’s stock valued at $1,665,585,000 after purchasing an additional 2,821,766 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in shares of Merck & Co., Inc. by 20.7% during the third quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company’s stock valued at $1,336,877,000 after purchasing an additional 2,735,459 shares during the period. Finally, Nordea Investment Management AB increased its holdings in shares of Merck & Co., Inc. by 2.0% during the third quarter. Nordea Investment Management AB now owns 10,945,187 shares of the company’s stock valued at $876,600,000 after purchasing an additional 209,759 shares during the period. 76.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Merck & Co., Inc.

In related news, EVP Richard R. Deluca sold 37,685 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the completion of the sale, the executive vice president directly owned 160,174 shares of the company’s stock, valued at $19,368,240.08. This represents a 19.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jennifer Zachary sold 121,573 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the sale, the executive vice president directly owned 68,916 shares of the company’s stock, valued at approximately $8,211,341.40. This represents a 63.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 320,176 shares of company stock valued at $38,281,735. Corporate insiders own 0.09% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on MRK. Deutsche Bank Aktiengesellschaft raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a report on Friday, February 13th. Bank of America raised their price target on Merck & Co., Inc. from $105.00 to $120.00 and gave the company a “buy” rating in a report on Monday, December 15th. Wells Fargo & Company raised their price target on Merck & Co., Inc. from $135.00 to $150.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. UBS Group raised their price target on Merck & Co., Inc. from $105.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Finally, Citigroup raised their price target on Merck & Co., Inc. from $120.00 to $125.00 and gave the company a “neutral” rating in a report on Friday, March 20th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and an average target price of $127.59.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: JPMorgan raised its price target on MRK to $135 and reiterated an Overweight rating, citing upside to the stock — a strong analyst endorsement that supports higher share valuations. JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock
• Positive Sentiment: Merck has commenced a cash tender offer to acquire Terns Pharmaceuticals, gaining early/mid‑stage oncology assets intended to shore up the pipeline ahead of upcoming patent expiries on key products — a strategically aligned M&A move that investors view as value‑accretive long term. Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
• Positive Sentiment: Fund commentary and coverage highlight Merck’s strong recent results and its appeal as a consistent dividend payer, reinforcing investor confidence in cash generation and yield support. (Includes JPMorgan’s broader endorsement noted above.) Strong Results Lifted Merck & Co (MRK) in Q4
• Neutral Sentiment: Analyst coverage pieces provide mixed context — some reiterate Merck’s defensive qualities and pipeline strength while flagging upcoming catalysts (earnings on April 30) that could swing sentiment. Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Agios Pharma (AGIO)
• Neutral Sentiment: Sector note: Q1 M&A activity in pharma is elevated — Merck’s deal fits a broader industry push to replenish pipelines, which is sector‑positive but increases deal execution and integration risk. Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
• Negative Sentiment: Merck lowered its offer price for Terns after reviewing trial data, which introduces short‑term uncertainty about the deal’s perceived value and may pressure sentiment around the acquisition. Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review
• Negative Sentiment: Merck shares showed a modest intraday decline (~1.3% in recent trade) while broader markets improved, signaling profit‑taking or headline sensitivity around the Terns deal and valuation debate. Merck (MRK) Stock Declines While Market Improves: Some Information for Investors
• Negative Sentiment: Commentary questioning whether defensive stocks like Merck are overbought may encourage short‑term selling among rotation traders despite positive fundamentals. Is It Too Late to Buy Costco or Merck? Are These Defensive Stocks Overbought?

Merck & Co., Inc. Stock Performance

Shares of NYSE MRK opened at $118.91 on Wednesday. The stock has a fifty day moving average price of $118.21 and a two-hundred day moving average price of $103.93. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. The firm has a market cap of $293.98 billion, a P/E ratio of 16.33, a PEG ratio of 2.44 and a beta of 0.26. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The firm had revenue of $16.40 billion during the quarter, compared to analyst estimates of $16.19 billion. During the same period last year, the company posted $1.72 EPS. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Research analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 16th were paid a dividend of $0.85 per share. The ex-dividend date of this dividend was Monday, March 16th. This represents a $3.40 annualized dividend and a yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio is currently 46.70%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.